TABLE 1.
(Data from https://clinicaltrials.gov, updated on 04-09–2023).
| Study title | Conditions | Interventions | Study phase | Outcome measures | Number of participants | Year of the study |
|---|---|---|---|---|---|---|
| “Oral Ondansetron Versus Transdermal Granisetron (Sancuso) for Women With Cervical, Endometrial or Vaginal Cancer Receiving Pelvic Chemoradiation” (15) | Cervical cancer | Ondansetron | Phase 3 | Percentage of Participating patients with a response rate to anti-emetic therapy days 4–7 of each chemotherapy cycle | 76 | 2019 |
| Percentage of Participating patients with a response rate to anti-emetic therapy at 0–24 h after each chemotherapy cycle | ||||||
| “Dexamethasone and Ondansetron Hydrochloride or Palonosetron Hydrochloride in Preventing Nausea and Vomiting in Patients Receiving Doxorubicin Hydrochloride and Cyclophosphamide for Early-Stage Breast Cancer” (16) | Male breast cancer | Ondansetron | Not applicable | Count of patients achieving complete response | 41 | 2017 |
| Number of days patients experienced emetic episodes and received rescue medication | ||||||
| Number of participating patients who experienced emesis within 48 h of receiving chemotherapy | ||||||
| “Ondansetron Versus Palonosetron Antiemetic Regimen Prior to Highly Emetogenic Chemotherapy (HEC)” (17) | Malignant neoplasm | Ondansetron | Not applicable | Overall complete response (CR), defined as no emesis and no rescue medication, following the initial course of HEC |
40 | 2011 |
| “Ondansetron Plus Dexamethasone With or Without Metoclopramide as Antiemetic Prophylaxis After Receiving Cisplatin” (18) | Cancer | Ondansetron | Not applicable | Number of patients who had a complete response Toxicities and severity of nausea and vomiting | 162 | 2010 |
| “Aprepitant in Preventing Nausea and Vomiting in Patients Who Are Undergoing a Stem Cell Transplant” (19) | Cancer | Ondansetron | Not applicable | Number of patients who remained emesis-free throughout the study period | 40 | 2009 |
| Safety in transplant population Changes to appetite and taste Effect on nausea | ||||||
| “Antiemetic Therapy With or Without Olanzapine in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients with Cancer Receiving Highly Emetogenic Chemotherapy” (20) | Hematopoietic/lymphoid cancer | Ondansetron | Phase 3 | The proportion of patients with no nausea | 401 | 2015 |
| Unspecified adult solid tumor | ||||||
| “Palonosetron Versus Ondansetron for the Prevention of Nausea and Vomiting” (21) | Acute myeloid leukemia | Ondansetron | Phase 2 | Number of patients with complete response (CR) | 150 | 2009 |
| “Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant” (22) | Accelerated phase chronic myeloid leukemia (CML) | Ondansetron | Phase 2 | Reduction in the rate of vomiting or nausea following ondansetron (when compared to historical FHCRC rates) | 49 | 2009 |
| Adult acute lymphoblastic leukemia (ALL) in remission Adult acute myeloid leukemia (AML) in remission | ||||||
| Adult AML with 11q23 (MLL gene) abnormalities | ||||||
| “Ondansetron Versus Aprepitant Plus Ondansetron for Emesis” (23) | Hematological diseases | Ondansetron | Phase 2 | Participant responses | 122 | 2013 |
| Acute myeloid leukemia (AML) | ||||||
| Myelodysplastic syndrome (MDS) | Treatment success rate | |||||
| Chronic myeloid leukemia (CML) | ||||||
| “A Korean Study of Efficacy and Safety of Aprepitant-based Triple Regimen for the Prevention of Chemotherapy-induced Nausea and Vomiting in the First Cycle of Moderately Emetogenic Chemotherapy (Non-doxorubicin Hydrochloride [Adriamycin] and Cyclophosphamide Regimens)” (24) | Nausea | Ondansetron | Phase 4 | Percentage of patients with no vomiting—overall stage | 494 | 2014 |
| Percentage of patients with a complete response (CR) –overall, delayed, and acute stages | ||||||
| Total number of emetic events—overall stage | ||||||
| Vomiting | Percentage of patients with no significant nausea and no vomiting—overall stage | |||||
| Percentage of patients having no impact on their day-to-day life—overall stage | ||||||
| Number of patients not needing to use a rescue therapy—overall, delayed and acute stages | ||||||
| Percentage of patients who experienced one or more clinical adverse event | ||||||
| Percentage of patients with no vomiting—acute and delayed stages | ||||||
| “Emend and Ondansetron Compared to Ondansetron Alone to Prevent CINV in Glioma Patients Receiving Temozolomide” (25) | Nausea Vomiting | Ondansetron | Phase 2 | The proportion of patients achieving complete control | 136 | 2017 |
| Glioma | The proportion of patients experiencing acute and delayed complete response (CR) | |||||
| Patient’s global satisfaction with the antiemetic regimen | ||||||
| “A Study of IV Casopitant for the Prevention of Chemotherapy Induced Nausea and Vomiting” (26) | Chemotherapy-induced nausea and vomiting | Ondansetron | Phase 3 | Maximum nausea score, evaluated using a visual analog scale (VAS) | 710 | 2009 |
| Percentage of patients receiving rescue medication | ||||||
| Percentage of patients who retched and/or vomited | ||||||
| Percentage of patients reporting significant nausea, defined as a maximum score that is ≥ 25 mm on the VAS | ||||||
| Percentage of patients reporting nausea, defined as a maximum score that is ≥ 5 mm on the VAS | ||||||
| Percentage of patients who experienced complete | ||||||
| protection, defined as complete responders | ||||||
| “Aprepitant’s Effect on Drug Metabolism in Multi-Day Combination (CHOP/R-CHOP) Chemotherapy Regimen in Lymphoma Patients” (27) | Lymphoma | Ondansetron | Not applicable | Ondansetron helped to prevent nausea and/or vomiting in patients with Non-Hodgkin’s Lymphoma | 23 | 2011 |